Table 3.

Clinical Trials in Advanced HCC.

.Drug	Trial name	Phase	Design	Endpoint	N	Start date	ClinicalTrials.gov	Status
Tremelimumab		II	Tremelimumab	ORR	20	December 2008	NCT01008358	Completed
Durvalumab, tremelimumab		II	Tremelimumab; Durvalumab; Tremelimumab 300 + Durvalumab; Tremelimumab 75 + Durvalumab	Safety, tolerability, and activity	433	19/10/2015	NCT02519348	Active, not recruiting
Durvalumab, tremelimumab	Himalaya	III	Durvalumab vs tremelimumab + durvalumab vs sorafenib	OS	1324	11/10/2017	NCT03298451	Active, not recruiting
Nivolumab, ipilimumab, cabozantinib	CheckMate 040	I/II	Nivolumab; nivolumab + ipilumumab; nivolumab + cabozantinib; nivolumab + ipilimumab + cabozantinib; sorafenib	ORR	1097	26/09/2012	NCT01658878	Active, not recruiting
Nivolumab	CheckMate 459	III	Nivolumab vs sorafenib	OS	743	25/11/2015	NCT02576509	Active, not recruiting
Pembrolizumab	KEYNOTE-224	II	Pembrolizumab	ORR	104	31/05/2016	NCT02702414	Active, not recruiting
Pembrolizumab	KEYNOTE-240	III	Pembrolizumab vs placebo	PFS and OS	413	26/05/2016	NCT02702401	Active, not recruiting
Atezolizumab, bevacizumab	GO30140	Ib	Atezolizumab + bevacizumab; atezolizumab	ORR and PFS	223	06/04/2016	NCT02715531	Active, not recruiting
Atezolizumab	IMbrave150	III	Atezolizumab + bevacizumab vs sorafenib	OS and PFS	501	15/03/2018	NCT03434379	Active, not recruiting